论文部分内容阅读
目的观察注射技术治疗急性特发性面神经麻痹的临床疗效.方法选取符合标准的126例急性期特发性面神经麻痹患者,将其随机分为治疗组90例和对照组36例.两组均每日给予神经生长因子18μg肌注与β-七叶皂苷钠15mg静脉滴注,治疗组还采用局部注射技术治疗.治疗4周后采用House-Brackmann(H-B)面神经功能评价分级系统进行疗效评价.结果治疗后两组组间H-B分级量表比较差异显著(P<0.01).治疗组总有效率为96.7%,对照组为80.6%,两组比较差异显著(P<0.05).结论注射技术治疗急性期特发性面神经麻痹临床疗效显著,在临床中值得进一步推广.“,”Objective: To observe the clinical efficacy of injection technology in the treatment of acute idiopathic facial paralysis.Methods: 126 cases with acute idiopathic facial paralysis were randomly divided into treatment group (90 cases)and control group (36 cases). Both groups were given daily intramuscular nerve growth factor 18μg and intravenous Aescine sodium 15mg, in addition the treatment group was treated with local injection technology. After 4 weeks’ treatment, evaluated the efficacy by House-Brackmann (HB) facial nerve function grading system. Results: The differences of the HB rating scale between the two groups after treatment were statisticaly significant (P<0.01); The total effective rate was 96.7% in the treatment group, 80.6% in the control group. The difference was statisticaly significant between the two groups (P<0.05). Conclusion:Injection technology has obvious therapeutic effect and significant clinical efficacy was worthy of further application of the clinics in treating idiopathic facial paralysis.